Brokerages expect Boston Scientific Corporation (NYSE:BSX) to announce sales of $2.20 billion for the current quarter, Zacks Investment Research reports. Ten analysts have provided estimates for Boston Scientific Corporation’s earnings. The highest sales estimate is $2.21 billion and the lowest is $2.19 billion. Boston Scientific Corporation reported sales of $2.11 billion in the same quarter last year, which indicates a positive year over year growth rate of 4.3%. The firm is expected to issue its next earnings report on Wednesday, October 25th.

On average, analysts expect that Boston Scientific Corporation will report full-year sales of $2.20 billion for the current financial year, with estimates ranging from $8.91 billion to $9.01 billion. For the next year, analysts forecast that the company will report sales of $9.58 billion per share, with estimates ranging from $9.47 billion to $9.70 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Boston Scientific Corporation.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period last year, the business earned $0.27 earnings per share. Boston Scientific Corporation’s revenue was up 6.2% compared to the same quarter last year.

BSX has been the subject of several analyst reports. J P Morgan Chase & Co reissued an “overweight” rating and issued a $31.00 target price (up from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Zacks Investment Research lowered shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Royal Bank Of Canada reissued a “buy” rating and issued a $31.00 target price on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. Wells Fargo & Company reissued an “outperform” rating and issued a $31.00 target price (up from $29.50) on shares of Boston Scientific Corporation in a report on Friday, June 16th. Finally, BidaskClub raised shares of Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $30.06.

In other news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $28.02, for a total transaction of $434,310.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP John Bradley Sorenson sold 7,900 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $26.37, for a total value of $208,323.00. Following the transaction, the senior vice president now owns 21,680 shares of the company’s stock, valued at $571,701.60. The disclosure for this sale can be found here. Insiders have sold a total of 236,489 shares of company stock valued at $6,440,888 over the last quarter. Corporate insiders own 0.74% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of BSX. FMR LLC increased its position in Boston Scientific Corporation by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after buying an additional 13,105,596 shares in the last quarter. Capital World Investors increased its position in Boston Scientific Corporation by 1.6% in the second quarter. Capital World Investors now owns 101,914,290 shares of the medical equipment provider’s stock worth $2,825,064,000 after buying an additional 1,611,442 shares in the last quarter. BlackRock Inc. increased its position in Boston Scientific Corporation by 4.6% in the second quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after buying an additional 4,439,966 shares in the last quarter. Vanguard Group Inc. increased its position in Boston Scientific Corporation by 2.8% in the second quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock worth $2,596,181,000 after buying an additional 2,522,556 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in Boston Scientific Corporation by 22,491.6% in the second quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after buying an additional 38,690,577 shares in the last quarter. Hedge funds and other institutional investors own 91.62% of the company’s stock.

WARNING: “Zacks: Brokerages Expect Boston Scientific Corporation (BSX) Will Post Quarterly Sales of $2.20 Billion” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/15/zacks-brokerages-expect-boston-scientific-corporation-bsx-will-post-quarterly-sales-of-2-20-billion.html.

Boston Scientific Corporation (NYSE:BSX) traded down 0.64% during trading on Tuesday, hitting $26.51. 2,201,917 shares of the stock were exchanged. The firm has a market capitalization of $36.38 billion, a price-to-earnings ratio of 47.42 and a beta of 1.09. The company has a 50-day moving average price of $27.30 and a 200 day moving average price of $26.10. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.51.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Get a free copy of the Zacks research report on Boston Scientific Corporation (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.